Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

[Development of cancer immunotherapy for urothelial carcinoma targeting tissue infiltrating regulatory T cells]

Original in Japanese: Development of cancer immunotherapy for urothelial carcinoma targeting tissue infiltrating regulatory T cells

Funder: Japan Society for the Promotion of Science

Funding period
JPY 4.3 M
USD 39 K
Funding amount
Abstract
[Although the anti-PD-1 antibody treatment has already been clinically applied to urothelial cancer, it is important to develop a novel immunotherapy having a higher therapeutic effect and less side effects. So far, we have found that the increase in regulatory T cell fraction in cancer tissue is involved as a characteristic of cases in which the anti-PD-1 antibody monotherapy is poor in effect. In this study, the possibility of therapeutic agents targeting regulatory T cells in cancer tissue against urothelial cancer is evaluated in (1) Xenograft model (2) spontaneous carcinogenesis model, and the cancer is examined by immunohistochemical staining using surgically resected specimens. The purpose of this study is to investigate the clinical significance of regulatory T cell expression in tissues and to develop new therapeutic strategies for urothelial cancer.]
Original in Japanese
抗PD-1抗体治療は尿路上皮癌において既に臨床応用されているが、より治療効果の高く副作用の少ない新規免疫療法の開発が重要である。これまで、我々は抗PD-1抗体単剤治療の効果が乏しい症例の特徴として、癌組織内における制御性T細胞分画の上昇が関与していることを見出した。当研究では、尿路上皮癌に対する癌組織内制御性T細胞を標的とした治療薬の可能性を、①Xenograftモデル②自然発がんモデルで評価すると共に、外科切除標本を用いた免疫組織化学染色により癌組織内制御性T細胞発現の臨床的意義を検討し、尿路上皮癌に対する新たなる治療戦略の創生を行うことを目的とする。
Similar projects All >
Sorted by: Start Date
Project list item
Characterization of Nectin-4 expression in molecular subtypes of urothelial cancer and mechanisms of resistance to enfortumab vedotin

Bladder Cancer Advocacy Network to Carissa Ellen Chu

USD 1,700
2020 - 2020
Project list item
Targeting regulatory B cells (Bregs) to improve anti-bladder cancer immunity

Bladder Cancer Advocacy Network to Burles Avner Johnson, David McConkey

USD 50,000
2020 - 2021
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
Effect of APOBEC3 on Bladder Cancer Biology and Response to Immunotherapy

National Cancer Institute to ANDREW TRUONG

USD 45,016
2020 - 2023

System

Categories
  • FOR (ANZSRC)

    1107 Immunology

  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Biotechnology

  • RCDC

    Cancer

  • RCDC

    Immunization

  • RCDC

    Urologic Diseases

  • RCDC

    Vaccine Related

  • HRCS HC

    Cancer

  • HRCS RAC

    2.1 Biological and endogenous factors

  • HRCS RAC

    5.1 Pharmaceuticals

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Basic Science